Browse > Article
http://dx.doi.org/10.5009/gnl17514

Optimal Starting Age for Colorectal Cancer Screening in an Era of Increased Metabolic Unhealthiness: A Nationwide Korean Cross-Sectional Study  

Choi, Yoon Jin (Department of Internal Medicine, Seoul National University Bundang Hospital)
Lee, Dong Ho (Department of Internal Medicine, Seoul National University Bundang Hospital)
Han, Kyung-Do (Department of Biostatistics, College of Medicine, The Catholic University of Korea)
Kim, Hyun Soo (Department of Internal Medicine, Seoul National University Bundang Hospital)
Yoon, Hyuk (Department of Internal Medicine, Seoul National University Bundang Hospital)
Shin, Cheol Min (Department of Internal Medicine, Seoul National University Bundang Hospital)
Park, Young Soo (Department of Internal Medicine, Seoul National University Bundang Hospital)
Kim, Nayoung (Department of Internal Medicine, Seoul National University Bundang Hospital)
Publication Information
Gut and Liver / v.12, no.6, 2018 , pp. 655-663 More about this Journal
Abstract
Background/Aims: The association between metabolic syndrome and colorectal cancer (CRC) has been suggested as one of causes for the increasing incidence of CRC, particularly in younger age groups. The present study examined whether the current age threshold (50 years) for CRC screening in Korea requires modification when considering increased metabolic syndrome. Methods: We analyzed data from the National Health Insurance Corporation database, which covers ~97% of the population in Korea. CRC risk was evaluated with stratification based on age and the presence/absence of relevant metabolic syndrome components (diabetes, dyslipidemia, and hypertension). Results: A total of 51,612,316 subjects enrolled during 2014 to 2015 were analyzed. Among them, 19.3% had diabetes, hypertension, dyslipidemia, or some combination thereof. This population had a higher incidence of CRC than did those without these conditions, and this was more prominent in subjects <40 years of age. The optimal cutoff age for detecting CRC, based on the highest Youden index, was 45 years among individuals without diabetes, dyslipidemia, and hypertension. Individuals with at least one of these components of metabolic syndrome had the highest Youden index at 62 years old, but the value was only 0.2. Resetting the cutoff age from 50 years to 45 years achieved a 6% increase in sensitivity for CRC detection among the total population. Conclusions: Starting CRC screening earlier, namely, at 45 rather than at 50 years of age, may improve secondary prevention of CRC in Korea.
Keywords
Colonic neoplasms; Screening; Youden index; Metabolic syndrome; Diabetes mellitus;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.   DOI
2 Jung KW, Won YJ, Oh CM, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat 2017;49:292-305.   DOI
3 Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.   DOI
4 American Cancer Society. Colorectal cancer facts & figures 2014- 2016 [Internet]. Atlanta: American Cancer Society [cited 2017 May 6]. Available from: http://www.cancer.org/research/cancerfacts- statistics/colorectal-cancer-facts-figures.html.
5 Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009;22:191-197.   DOI
6 U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:627-637.   DOI
7 Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin 2017;67:177-193.   DOI
8 Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome. Circulation 2009;120:1640-1645.   DOI
9 Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev 2007;16:2533-2547.   DOI
10 Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and metaanalysis. Diabetes Care 2012;35:2402-2411.   DOI
11 Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-35.   DOI
12 Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: the National Health Insurance Service-National Sample Cohort (NHISNSC), South Korea. Int J Epidemiol 2017;46:e15.
13 Yang HK, Han K, Kwon HS, et al. Obesity, metabolic health, and mortality in adults: a nationwide population-based study in Korea. Sci Rep 2016;6:30329.   DOI
14 Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF. Youden index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J 2008;50:419-430.   DOI
15 de Kort S, Masclee AA, Sanduleanu S, et al. Higher risk of colorectal cancer in patients with newly diagnosed diabetes mellitus before the age of colorectal cancer screening initiation. Sci Rep 2017;7:46527.   DOI
16 Ranc K, Jorgensen ME, Friis S, Carstensen B. Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia 2014;57:927-934.   DOI
17 Riaz R, Masood N, Benish A. Red flag symptoms: detailed account of clinicopathological features in young-onset colorectal cancer. Intest Res 2017;15:203-207.   DOI
18 Ginter E, Simko V. Type 2 diabetes mellitus, pandemic in 21st century. Adv Exp Med Biol 2012;771:42-50.
19 Ahrens W, Moreno LA, Marild S, et al. Metabolic syndrome in young children: definitions and results of the IDEFICS study. Int J Obes (Lond) 2014;38 Suppl 2:S4-S14.   DOI
20 Pelucchi C, Negri E, Talamini R, et al. Metabolic syndrome is associated with colorectal cancer in men. Eur J Cancer 2010;46:1866-1872.   DOI
21 Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G. Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. Dis Colon Rectum 2013;56:1304-1319.   DOI
22 Yang MH, Rampal S, Sung J, et al. The association of serum lipids with colorectal adenomas. Am J Gastroenterol 2013;108:833-841.   DOI
23 Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a metaanalysis of prospective studies. Cancer Causes Control 2015;26:257-268.   DOI
24 Stein KB, Snyder CF, Barone BB, et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Dig Dis Sci 2010;55:1839-1851.   DOI
25 Chen KH, Shao YY, Lin ZZ, et al. Type 2 diabetes mellitus is associated with increased mortality in Chinese patients receiving curative surgery for colon cancer. Oncologist 2014;19:951-958.   DOI
26 Yap R, Wilkins S, Staples M, Oliva K, McMurrick PJ. The effect of diabetes on the perioperative outcomes of colorectal cancer surgery patients. PLoS One 2016;11:e0167271.   DOI
27 Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-2192.   DOI
28 European Colorectal Cancer Screening Guidelines Working Group, von Karsa L, Patnick J, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 2013;45:51-59.   DOI
29 Huang CW, Sun LC, Shih YL, et al. The impact on clinical outcome of high prevalence of diabetes mellitus in Taiwanese patients with colorectal cancer. World J Surg Oncol 2012;10:76.   DOI
30 Sohn DK, Kim MJ, Park Y, et al. The Korean guideline for colorectal cancer screening. J Korean Med Assoc 2015;58:420-432.   DOI
31 Shin CM, Han K, Lee DH, et al. Association among obesity, metabolic health, and the risk for colorectal cancer in the general population in Korea using the National Health Insurance Service-National Sample Cohort. Dis Colon Rectum 2017;60:1192-1200.   DOI
32 Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening:recommendations for physicians and patients from the U.S. Multi-Society Task Force on colorectal cancer. Gastroenterology 2017;153:307-323.   DOI
33 Jung YS. Is colorectal cancer screening necessary before 50 years of age? Intest Res 2017;15:550-551.   DOI
34 Jung YS, Park CH, Kim NH, Park JH, Park DI, Sohn CI. Colorectal cancer screening with the fecal immunochemical test in persons aged 30 to 49 years: focusing on the age for commencing screening. Gastrointest Endosc 2017;86:892-899.   DOI
35 Stoffel EM, Koeppe E, Everett J, et al. Germline genetic features of young individuals with colorectal cancer. Gastroenterology 2018;154:897-905.e1.   DOI